Payment overview · 2025
General Payments
$2,275.88
141 reported records · 33 companies
Healthcare provider profile · identity verified
Anju Lele, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MENTOR, OH · NPI 1558467423
Verified facts
What the public records show
CMS Open Payments records show Anju Lele, MD received $2,275.88 in general payments during 2025 across 141 reported records.
Astellas Pharma US Inc accounted for 7.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 53 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Ozempic, Synthroid, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Vraylar by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Myrbetriq by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 175 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Wegovy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 175 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $170.61 | 7.5% | 9 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $169.90 | 7.5% | 12 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $163.71 | 7.2% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $163.33 | 7.2% | 12 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $146.64 | 6.4% | 11 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $105.14 | 4.6% | 5 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $103.12 | 4.5% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $98.32 | 4.3% | 6 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $76.58 | 3.4% | 3 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $73.14 | 3.2% | 4 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $73.11 | 3.2% | 18 | 2025 |
| BETA BIONICS, INC. | Unresolved — no canonical attribution shown | $71.99 | 3.2% | 4 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $71.13 | 3.1% | 4 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $69.29 | 3.0% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $65.31 | 2.9% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $59.12 | 2.6% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $56.31 | 2.5% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $55.88 | 2.5% | 2 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $52.01 | 2.3% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $49.93 | 2.2% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $46.48 | 2.0% | 3 | 2025 |
| VIVUS LLC | Unresolved — no canonical attribution shown | $40.11 | 1.8% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $39.11 | 1.7% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $38.46 | 1.7% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $36.47 | 1.6% | 2 | 2025 |
| Cipher Pharmaceuticals US LLC | Unresolved — no canonical attribution shown | $31.10 | 1.4% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $30.64 | 1.4% | 2 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $28.50 | 1.2% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $25.27 | 1.1% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$17.88 | 0.8% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $16.76 | 0.7% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $15.79 | 0.7% | 1 | 2025 |
| Ascensia Diabetes Care Us Inc. | Unresolved — no canonical attribution shown | $14.74 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,275.88 | 141 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $170.61 | 9 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $146.64 | 11 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $120.48 | 8 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $115.43 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $115.01 | 9 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $105.14 | 5 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $103.12 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $98.32 | 6 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $82.92 | 6 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $82.92 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $81.47 | 5 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $80.79 | 4 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $76.58 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $73.11 | 18 | 2025 |
Source payment records
|
|||||
| iLet Bionic Pancreas Normalized: ilet bionic pancreas |
Device | BETA BIONICS, INC. | $71.99 | 4 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Contact Detach Normalized: ilet insulin infusion kit contact detach |
Device | BETA BIONICS, INC. | $71.99 | 4 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Inset Normalized: ilet insulin infusion kit inset |
Device | BETA BIONICS, INC. | $71.99 | 4 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $71.13 | 4 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $69.29 | 3 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $69.29 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $66.11 | 4 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $55.88 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $54.89 | 3 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $54.79 | 3 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $52.01 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $49.93 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $48.35 | 3 | 2025 |
Source payment records
|
|||||
| QSYMIA Normalized: qsymia |
Drug | VIVUS LLC | $40.11 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $39.11 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $38.46 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $36.47 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $32.90 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $32.49 | 2 | 2025 |
Source payment records
|
|||||
| Natroba Normalized: natroba |
Drug | Cipher Pharmaceuticals US LLC | $31.10 | 1 | 2025 |
Source payment records
|
|||||
| Spinosad Normalized: spinosad |
Drug | Cipher Pharmaceuticals US LLC | $31.10 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $30.66 | 3 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $30.64 | 2 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $28.50 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $28.45 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $25.27 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $18.68 | 1 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $18.35 | 1 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $17.88 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $17.75 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $16.96 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $16.96 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $16.96 | 1 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $16.76 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $15.86 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $15.79 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $13.58 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $13.58 | 1 | 2025 |
Source payment records
|
|||||
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $4.09 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 175 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 42 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 45 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 62 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
62 | 22 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
175 | 48 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
42 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
45 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
175 | 48 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 994 | 312 |
| Levothyroxine Sodium | Levothyroxine Sodium | 759 | 208 |
| Metoprolol Succinate | Metoprolol Succinate | 645 | 207 |
| Pantoprazole Sodium | Pantoprazole Sodium | 554 | 201 |
| Amlodipine Besylate | Amlodipine Besylate | 488 | 161 |
| Lisinopril | Lisinopril | 369 | 115 |
| Losartan Potassium | Losartan Potassium | 363 | 128 |
| Gabapentin | Gabapentin | 290 | 92 |
| Metformin Hcl | Metformin Hcl | 275 | 89 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 263 | 95 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 261 | 96 |
| Furosemide | Furosemide | 253 | 81 |
| Omeprazole | Omeprazole | 245 | 76 |
| Simvastatin | Simvastatin | 194 | 48 |
| Tamsulosin Hcl | Tamsulosin Hcl | 193 | 61 |
| Metoprolol Tartrate | Metoprolol Tartrate | 185 | 55 |
| Glimepiride | Glimepiride | 181 | 58 |
| Sertraline Hcl | Sertraline Hcl | 181 | 48 |
| Eliquis | Apixaban | 175 | 48 |
| Potassium Chloride | Potassium Chloride | 161 | 51 |
| Duloxetine Hcl | Duloxetine Hcl | 150 | 47 |
| Azithromycin | Azithromycin | 139 | 116 |
| Fluticasone Propionate | Fluticasone Propionate | 139 | 59 |
| Trazodone Hcl | Trazodone Hcl | 130 | 41 |
| Fenofibrate | Fenofibrate Nanocrystallized | 124 | 30 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 98 | 56 |
| Clopidogrel | Clopidogrel Bisulfate | 93 | 37 |
| Januvia | Sitagliptin Phosphate | 87 | 25 |
| Cephalexin | Cephalexin | 85 | 69 |
| Atenolol | Atenolol | 79 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 75 | 28 |
| Methylprednisolone | Methylprednisolone | 75 | 66 |
| Escitalopram Oxalate | Escitalopram Oxalate | 70 | 25 |
| Xarelto | Rivaroxaban | 70 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 66 | 20 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 64 | 46 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 63 | 43 |
| Synthroid | Levothyroxine Sodium | 62 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 58 | 18 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 57 | 44 |
| Buspirone Hcl | Buspirone Hcl | 57 | 16 |
| Ezetimibe | Ezetimibe | 57 | 23 |
| Montelukast Sodium | Montelukast Sodium | 57 | 15 |
| Ibandronate Sodium | Ibandronate Sodium | 54 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 53 | 18 |
| Carvedilol | Carvedilol | 51 | 20 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 49 | 18 |
| Alendronate Sodium | Alendronate Sodium | 48 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 48 | 18 |
| Warfarin Sodium | Warfarin Sodium | 47 | 13 |
| Ozempic | Semaglutide | 45 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 44 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 42 | 11 |
| Mounjaro | Tirzepatide | 42 | 11 |
| Allopurinol | Allopurinol | 41 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 41 | 32 |
| Prednisone | Prednisone | 40 | 35 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 39 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 39 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 38 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 37 | 11 |
| Nystatin | Nystatin | 35 | 22 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 34 | 30 |
| Breo Ellipta | Fluticasone/Vilanterol | 33 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 33 | suppressed |
| Myrbetriq | Mirabegron | 32 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 32 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 31 | 13 |
| Clonidine Hcl | Clonidine Hcl | 30 | suppressed |
| Spironolactone | Spironolactone | 30 | 17 |
| Pregabalin | Pregabalin | 29 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 28 | 11 |
| Famotidine | Famotidine | 28 | 11 |
| Cefuroxime | Cefuroxime Axetil | 27 | 26 |
| Farxiga | Dapagliflozin Propanediol | 27 | 12 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 27 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 27 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 26 | 13 |
| Klor-Con M20 | Potassium Chloride | 26 | 12 |
| Nabumetone | Nabumetone | 26 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 26 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 26 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 25 | suppressed |
| Lansoprazole | Lansoprazole | 25 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 25 | 23 |
| Jantoven | Warfarin Sodium | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | 16 |
| Solifenacin Succinate | Solifenacin Succinate | 23 | 11 |
| Bupropion Xl | Bupropion Hcl | 21 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Klor-Con | Potassium Chloride | 21 | suppressed |
| Lactulose | Lactulose | 21 | 14 |
| Lovastatin | Lovastatin | 21 | suppressed |
| Mirtazapine | Mirtazapine | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Valsartan | Valsartan | 21 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 20 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 18 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 18 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 18 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Vraylar | Cariprazine Hcl | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | 15 |
| Ondansetron Odt | Ondansetron | 15 | 11 |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Jardiance | Empagliflozin | 14 | suppressed |
| Repatha Sureclick | Evolocumab | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | 11 |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Dexamethasone | Dexamethasone | 13 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | 12 |
| Dutasteride | Dutasteride | 13 | suppressed |
| Estradiol | Estradiol | 13 | 11 |
| Metronidazole | Metronidazole | 13 | 13 |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | 11 |
| Fluconazole | Fluconazole | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Finasteride | Finasteride | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Levemir | Insulin Detemir | 11 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Wegovy | Semaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,275.88 · 141 records | Astellas Pharma US Inc | ABRYSVO, AFREZZA, AREXVY, AUSTEDO XR, Auvelity, CAPLYTA, CAPVAXIVE, COBENFY, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FREESTYLE LIBRE 3, GARDASIL 9, GEMTESA, GVOKE HYPOPEN, JARDIANCE, Korlym, LEQVIO, MINIMED 780G, MOUNJARO, NURTEC ODT, Natroba, OTEZLA, Omnipod, Ozempic, PREVNAR 20, PROLIA, QSYMIA, QULIPTA, RECORLEV, REPATHA, REXULTI, Rybelsus, SHINGRIX, SKYRIZI, SYNTHROID, Spinosad, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, WATCHMAN FLX, YUPELRI, ZAVZPRET, ZENPEP, ZEPBOUND, ZORYVE, iLet Bionic Pancreas, iLet Insulin Infusion Kit Contact Detach, iLet Insulin Infusion Kit Inset | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error